Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 17, Issue 2, Pages 115-120
http://dx.doi.org/10.1155/2001/239602

ANX7 as a Bio-Marker in Prostate and Breast Cancer Progression

Meera Srivastava,1 Lukas Bubendorf,2,5 Lisa Nolan,1 Mirta Glasman,1 Ximena Leighton,1 Georgina Miller,3 Wilfred Fehrle,4 Mark Raffeld,4 Ofer Eidelman,1 Olli P. Kallioniemi,2 Shiv Srivastava,6 and Harvey B. Pollard1

1Department of Anatomy, Physiology and Genetics, and Institute for Molecular Medicine, Uniformed Services University School of Medicine (USUHS), Bethesda, MD 20814, USA
2Section on Molecular Genetics, Cancer Genetics Branch, NHGRI, National Institutes of Health, Bethesda, MD 20892, USA
3Veterinary Resources Program, NCRR, National Institutes of Health, Bethesda, MD 20892, USA
4Laboratory of Pathology, Hematopathology section, NCI, NIH, Bethesda, MD 20892, USA
5Institute for Pathology, University of Basel, Switzerland
6Center for Prostate Disease Research, and Department of Surgery, Uniformed Services University School of Medicine (USUHS), Bethesda, MD 20814, USA

Received 20 September 2001; Accepted 20 September 2001

Copyright © 2001 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The ANX7 gene codes for a Ca2+-activated GTPase, which has been implicated in both exocytotic secretion in cells and control of growth. In this review, we summarize information regarding increased tumor frequency in the Anx7 knockout mice, ANX7 growth suppression of human cancer cell lines, and ANX7 expression in human tumor tissue micro-arrays. The loss of ANX7 is significant in metastatic and hormone refractory prostate cancer compared to benign prostatic hyperplasia. In addition, ANX7 expression has prognostic value for predicting survival of breast cancer patients.